Stock listing
DMAC Stock Price, News, Filings & Events — Diamedica Therapeutics Inc.
Selected listing: DMAC · BOATS · USD · US
This page tracks Diamedica Therapeutics Inc.'s DMAC:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following DMAC:BOATS. DMAC:BOATS is the stock-level entry point for investors researching Diamedica Therapeutics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Diamedica Therapeutics Inc. (Ticker: DMAC) is a public company based in America with a market capitalization of approximately $362.9 million. The company focuses on developing innovative therapies for neurological diseases. Its commitment to advancing healthcare solutions positions it as a notable player in the biotechnology sector.
- Ticker
- DMAC:BOATS
- Asset type
- Stock
- Market cap
- $344.6M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Diamedica Therapeutics Inc. DMAC:BOATS stock context
This page tracks Diamedica Therapeutics Inc.'s DMAC:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following DMAC:BOATS. DMAC:BOATS is the stock-level entry point for investors researching Diamedica Therapeutics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Diamedica Therapeutics Inc. (Ticker: DMAC) is a public company based in America with a market capitalization of approximately $362.9 million. The company focuses on developing innovative therapies for neurological diseases. Its commitment to advancing healthcare solutions positions it as a notable player in the biotechnology sector.
Latest news from Diamedica Therapeutics Inc.
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 10, 2026
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
August 4, 2026
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
June 23, 2026
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
June 16, 2026
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
May 27, 2026
Diamedica Therapeutics Inc. earnings calls
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call
August 11, 2026 · Replay with transcript and chapters
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call
May 7, 2026 · Replay with transcript and chapters
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call
March 31, 2026 · Replay with transcript and chapters
DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call
November 13, 2025 · Replay with transcript and chapters
DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call
August 13, 2025 · Replay with transcript and chapters
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call
May 14, 2025 · Replay with transcript and chapters
Research Diamedica Therapeutics Inc.
Diamedica Therapeutics Inc. investor report
Review AI stock analysis and investor report context for DMAC:BOATS.
Diamedica Therapeutics Inc. company profile
View the public company page for Diamedica Therapeutics Inc. on 6ix.
Diamedica Therapeutics Inc. news
Read company news and market updates connected to Diamedica Therapeutics Inc..
Diamedica Therapeutics Inc. investor events
Find investor webinars, events, and replay context for Diamedica Therapeutics Inc..